Jafron Biomedical Co

Jafron Biomedical Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is -8.73 M CNY. In the previous year, Stock-Based Compensation (SBC) was 7.52 M CNY — a change of -216.19% (lower).

Stock-Based Compensation

-8.73 MCNY

YoY

-216.19%

Last updated:

Stock-Based Compensation (SBC) of Jafron Biomedical Co is 2022 -8.73 M CNY. Stock-Based Compensation (SBC) of Jafron Biomedical Co was 2021 7.52 M CNY. It decreases by -216.19% lower compared to the previous year.

The Jafron Biomedical Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2017
5.02 M CNY
Jan 1, 2018
11.31 M CNY
Jan 1, 2019
17.13 M CNY
Jan 1, 2020
22.35 M CNY
Jan 1, 2021
7.52 M CNY
Jan 1, 2022
-8.73 M CNY
The Jafron Biomedical Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
-8.73 MCNY-216.19%
7.52 MCNY-66.37%
22.35 MCNY+30.50%
17.13 MCNY+51.40%
11.31 MCNY+125.39%
5.02 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Stock-Based Compensation (SBC) of Jafron Biomedical Co is -8.73 M CNY in 2022.

Stock-Based Compensation (SBC) of Jafron Biomedical Co changed from 7.52 M CNY to -8.73 M CNY, representing a -216.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co